检索规则说明:AND代表“并且”;OR代表“或者”;NOT代表“不包含”;(注意必须大写,运算符两边需空一格)
检 索 范 例 :范例一: (K=图书馆学 OR K=情报学) AND A=范并思 范例二:J=计算机应用与软件 AND (U=C++ OR U=Basic) NOT M=Visual
作 者:欧娅[1] 贾林[1] 邱嘉华[1] 李伟冬[1] 黄耀星[1] 聂玉强[1]
机构地区:[1]广州医学院附属广州市第一人民医院消化内科,510180
出 处:《中华胰腺病杂志》2012年第1期49-51,共3页Chinese Journal of Pancreatology
基 金:广东省中医药局科研课题(008006)、广州市中西医结合科研课题(2008A02)
摘 要:目的探讨infliximab(TNF-α单抗)对大鼠急性坏死性胰腺炎(ANP)并多器官功能障碍综合征(MODS)模型肠动力及肠屏障损害的保护作用。方法30只SD大鼠按完全随机法分为假手术组、ANP组和infliximab组。经胰胆管逆行注射4.5%牛磺胆酸钠制备大鼠ANP并MODS模型,infliximab组于建模后6h经尾静脉给予infliximab8mg/kg体重,对照组胰胆管逆行注射等量生理盐水。24h后处死大鼠,检测血淀粉酶、TNF—α水平及二胺氧化酶(DAO)、D.乳酸含量;胰腺及小肠组织常规病理检查及评分;碳素墨水法测小肠推进率。结果对照组、ANP组、infliximab组血清淀粉酶水平分别为(1125±331)、(11024±2203)、(545±30)U/L;TNF-d水平为(12.1±4.0)、(107.6±18.5)、(75.8±5.9)U/L;胰腺病理评分为(2.25±0.38)、(14.1±0.22)、(3.93±0.67)分;小肠病理评分为(2.29±0.32)、(6.61±0.58)、(3.91±0.41)分;血清DAO含量为(87.88±34.51)、(146.30±12.99)、(115.00±18.58)μG/L;D-乳酸含量为(1.50±0.49)、(2.32±0.35)、(2.02±0.25)mmol/L;小肠推进率为(0.64±0.04)%、(0.28±0.08)%、(0.52±0.09)%,各组间比较差异均有统计学意义(P值均〈0.05)。结论早期使用infliximab可有效改善ANP大鼠的胃肠动力功能及减轻肠屏障损害。Objective To evaluate the effects of infliximab (TNF-α monoclonal antibody ) on intestinal barrier injury in ANP complicated with MODS in a rat model. Methods Thirty SD rats were randomly divided into sham operation group (SO), ANP group and infliximab treatment group. Sodium taurocholate (4.5%) was injected into the pancreatic duct to induce ANP complicated with MODS model. Infliximab (8 mg/kg) was injected via tail vein in 6h after modeling in infliximab group. Same amount of 0.9% NS was injected into the pancreatic duct in SO group. After 24 h of modeling, all rats were sacrificed, intestine and pancreas samples were collected for pathologic examination. The blood samples were harvested. The serum levels of amylase, TNF-cx, diamine oxidase( DAO), D-lactate, and the rate of carbon propelling in ileum were measured. Results The serum levels of amylase were (1125 ± 331 ), (11024 ± 2203 ), (545 ± 30) U/L in SO group, ANP group and infliximab group; the serum levels of TNF-α were (12.1 ± 4.0), (107.6 ±18.5), (75.8 ±5.9)U/L; the pathological scores of pancreas were 2.25 ±0.38, 14.10 ±0.22, 3.93 _± 0.67, the difference among the 3 groups was statistically significant ( P 〈 0.05 ). The pathological scores of intestine were 2.29 ± 0.32, 6.61 ± 0.58, 3.91 ± 0.41 ; the DAO levels were (87.88 ± 34.51 ),( 146.30 ± 12.99), ( 115.00 ± 18.58 ) ng/ml; the D-lactate levels were ( 1.50 ±0.49 ), ( 2.32 ± 0.35 ), (2.02±0.25) retool/L; and the rates of carbon propelling in ileum were (0.64 ±0.04)%, (0.28 ± 0.08 ) %, ( 0.52 ±0.09 ) % , the difference among the 3 groups was statistically significant ( P 〈 0.05 ). Conclusions Infliximab can effectively prevent dysfunction of intestinal barrier and improve motility in ANP rats.
正在载入数据...
正在载入数据...
正在载入数据...
正在载入数据...
正在载入数据...
正在载入数据...
正在载入数据...
正在链接到云南高校图书馆文献保障联盟下载...
云南高校图书馆联盟文献共享服务平台 版权所有©
您的IP:216.73.216.249